MEPACT
Dead / Cancelled — Cancelled — Section 8 (as of 22 Feb 2013)
What this means for you
This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 78524381
- Registration number
- 3116184
- Mark type
- Stylized text
- Filed
- 30 Nov 2004
- Published for opposition
- 25 Apr 2006
- Registered
- 18 Jul 2006
- Attorney of record
- Dennis A. Bennett
Goods and services
- Class 001 — Chemicals: Chemicals for use in the manufacture of preparations for medical or veterinary use, particularly muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2 (1, 2-dipalmitoyl-sn-g lycero-3-hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all of these products being more specifically meant to be used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy
- Class 005 — Pharmaceuticals: Preparations for medical or veterinary use, particularly muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), N-acetylmuramyl-L-alanyl- D-isoglutaminyl-L-alanine-2 (1, 2-dipalmitoyl-sn-qlycero-3-hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, and pharmaceutically acceptable salts of muramyl peptides, all of these products being more specifically meant to be used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations for anti-cancer and antiviral therapies, neoplasia, and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy
Owner
- I.D.M. IMMUNO-DESIGNED MOLECULES, Paris, FR
- I.D.M. IMMUNO-DESIGNED MOLECULES, Paris, FR
- I.D.M. IMMUNO-DESIGNED MOLECULES, Paris, FR
Prosecution history
- 22 Feb 2013 — CANCELLED SEC. 8 (6-YR)
- 03 Dec 2010 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 01 Sept 2010 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 16 Oct 2009 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 16 Oct 2009 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 01 May 2008 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 16 Mar 2008 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 Jul 2006 — REGISTERED-PRINCIPAL REGISTER
- 25 Apr 2006 — PUBLISHED FOR OPPOSITION
- 05 Apr 2006 — NOTICE OF PUBLICATION
- 02 Mar 2006 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 01 Mar 2006 — ASSIGNED TO LIE
- 08 Feb 2006 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Jan 2006 — AMENDMENT FROM APPLICANT ENTERED
- 04 Jan 2006 — CORRESPONDENCE RECEIVED IN LAW OFFICE